Biontech Se Stock Revenue
| BNTX Stock | USD 98.96 1.90 1.88% |
BioNTech SE fundamentals help investors to digest information that contributes to BioNTech's financial success or failures. It also enables traders to predict the movement of BioNTech Stock. The fundamental analysis module provides a way to measure BioNTech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BioNTech stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 2.8 B | 2.6 B |
BioNTech | Revenue |
BioNTech SE Company Revenue Analysis
BioNTech's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current BioNTech Revenue | 2.75 B |
Most of BioNTech's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioNTech SE is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of BioNTech
Projected quarterly revenue analysis of BioNTech SE provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of BioNTech match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in BioNTech's stock price.
BioNTech Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for BioNTech is extremely important. It helps to project a fair market value of BioNTech Stock properly, considering its historical fundamentals such as Revenue. Since BioNTech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of BioNTech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of BioNTech's interrelated accounts and indicators.
| 0.18 | 0.17 | -0.76 | 0.2 | 0.51 | ||
| 0.18 | 0.98 | -0.69 | 1.0 | 0.85 | ||
| 0.17 | 0.98 | -0.68 | 0.98 | 0.83 | ||
| -0.76 | -0.69 | -0.68 | -0.71 | -0.83 | ||
| 0.2 | 1.0 | 0.98 | -0.71 | 0.85 | ||
| 0.51 | 0.85 | 0.83 | -0.83 | 0.85 |
Click cells to compare fundamentals
BioNTech Revenue Historical Pattern
Today, most investors in BioNTech Stock are looking for potential investment opportunities by analyzing not only static indicators but also various BioNTech's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's revenue growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of BioNTech revenue as a starting point in their analysis.
BioNTech Revenue |
| Timeline |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
BioNTech Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, BioNTech SE reported 2.75 B of revenue. This is 63.93% lower than that of the Biotechnology sector and 270.31% higher than that of the Health Care industry. The revenue for all United States stocks is 70.84% higher than that of the company.
BioNTech Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioNTech's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BioNTech could also be used in its relative valuation, which is a method of valuing BioNTech by comparing valuation metrics of similar companies.BioNTech is currently under evaluation in revenue category among its peers.
BioNTech ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, BioNTech's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to BioNTech's managers, analysts, and investors.Environmental | Governance | Social |
BioNTech Institutional Holders
Institutional Holdings refers to the ownership stake in BioNTech that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of BioNTech's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing BioNTech's value.| Shares | Capital International Inc /ca/ | 2024-12-31 | 668.3 K | Altrinsic Global Advisors Llc | 2024-12-31 | 627.5 K | Bnp Paribas Arbitrage, Sa | 2024-12-31 | 614.3 K | Ubs Group Ag | 2024-12-31 | 529.1 K | Dz Bank Ag Deutsche Zentral-genossenschaftsbank Frankfurt Am Main | 2024-12-31 | 501.9 K | Dekabank Deutsche Girozentrale | 2024-12-31 | 481.4 K | Fred Alger Management, Llc | 2024-12-31 | 465.4 K | Aberdeen Group Plc | 2024-12-31 | 385.7 K | Squarepoint Ops Llc | 2024-12-31 | 369.6 K | Baillie Gifford & Co Limited. | 2024-12-31 | 8.2 M | Fmr Inc | 2024-12-31 | 7.7 M |
BioNTech Fundamentals
| Return On Equity | -0.0336 | ||||
| Return On Asset | -0.0353 | ||||
| Profit Margin | (0.24) % | ||||
| Operating Margin | 0.13 % | ||||
| Current Valuation | 6.16 B | ||||
| Shares Outstanding | 239.97 M | ||||
| Shares Owned By Insiders | 63.22 % | ||||
| Shares Owned By Institutions | 22.00 % | ||||
| Number Of Shares Shorted | 3.02 M | ||||
| Price To Earning | 5.19 X | ||||
| Price To Book | 1.14 X | ||||
| Price To Sales | 8.80 X | ||||
| Revenue | 2.75 B | ||||
| Gross Profit | 2.21 B | ||||
| EBITDA | (367.1 M) | ||||
| Net Income | (677.7 M) | ||||
| Cash And Equivalents | 9.33 B | ||||
| Cash Per Share | 38.30 X | ||||
| Total Debt | 254.2 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 5.15 X | ||||
| Book Value Per Share | 80.89 X | ||||
| Cash Flow From Operations | 207.7 M | ||||
| Short Ratio | 3.62 X | ||||
| Earnings Per Share | (3.01) X | ||||
| Price To Earnings To Growth | 0.04 X | ||||
| Target Price | 139.27 | ||||
| Number Of Employees | 6.77 K | ||||
| Beta | 0.31 | ||||
| Market Capitalization | 24.2 B | ||||
| Total Asset | 22.53 B | ||||
| Retained Earnings | 19.1 B | ||||
| Working Capital | 16.28 B | ||||
| Current Asset | 284.67 M | ||||
| Current Liabilities | 143.37 M | ||||
| Net Asset | 22.53 B |
About BioNTech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BioNTech SE's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioNTech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioNTech SE based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for BioNTech Stock Analysis
When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.